Potent anti-muscarinic activity in a novel series of quinuclidine derivatives

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 2, 2006, Pages 373-377

  Starck, Jean Philippe ^a   Talaga, Patrice ^a   Quéré, Luc ^a   Collart, Philippe ^a   Christophe, Bernard ^a   Brutto, Patrick Lo ^a   Jadot, Sophie ^a   Chimmanamada, Dinesh ^b   Zanda, Matteo ^b   Wagner, Alain ^b   Mioskowski, Charles ^b   Massingham, Roy ^a   Guyaux, Michel ^a  

^a UCB PHARMA   (Belgium)

^b UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Bladder; Muscarinic antagonist(s); Muscarinic receptor(s); Overactive bladder; Quinuclidine; Urinary incontinence

Indexed keywords

ALKYNE DERIVATIVE; MUSCARINIC AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; QUINUCLIDINE DERIVATIVE;

ARTICLE; CHEMICAL MODIFICATION; DRUG ACTIVITY; DRUG SYNTHESIS;

ANIMALS; BINDING SITES; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG EVALUATION, PRECLINICAL; GUINEA PIGS; HUMANS; MICROSOMES; MOLECULAR STRUCTURE; MUSCARINIC ANTAGONISTS; QUINUCLIDINES; RECEPTORS, MUSCARINIC; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 27944511356     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2005.09.079     Document Type: Article

References (29)

1. K.-E. Andersson Lancet Neurol. 3 2004 46
2. S.S. Hegde, M. Mammen, and J.R. Jasper Curr. Opin. Investig. Drugs 5 2004 40
3. R.M. Eglen, A. Choppin, and N. Watson Trends Pharmacol. Sci. 22 2001 409
4. M. Feinberg Drugs Aging. 3 1993 335
5. H.M. Scarpero, and R.R. Dmochowski Curr. Urol. Rep. 4 2003 421
6. O. Diouf, S. Gadeau, F. Chellé, M. Gelbcke, P. Talaga, B. Christophe, M. Gillard, R. Massingham, and M. Guyaux Bioorg. Med. Chem. Lett. 12 2002 2535
7. Guyaux, M.; Dinesh, C. U.; Mioskowski, C.; Quere, L.; Starck, J.-P.; Talaga, P.; Wagner, A.; Zanda, M. WO 03/033495, 2003.
8. N. Mealy, and J. Castaner Drugs Future 24 1999 871
9. P.L. Stotter, M.D. Friedman, G.O. Dorsey, R.W. Shiely, R.F. Williams, and D.E. Minter Heterocycles 25 1987 251
10. 4OH 94/6/1). 3-[(3R)-3-Methoxy-1-azabicyclo[2.2.2]oct-3-yl]-1,1- diphenyl-2-propyn-1-ol 3a was obtained as a white solid (20.9 g, 83%).
11. M. Mitsuya, T. Mase, Y. Tsuchiya, K. Kawakami, H. Hattori, K. Kobayashi, Y. Ogino, T. Fujikawa, A. Satoh, T. Kimura, K. Noguchi, N. Ohtake, and K. Tomimoto Bioorg. Med. Chem. 7 1999 2555
12. R. Naito, M. Takeuchi, K. Morihira, M. Hayakawa, K. Ikeda, T. Shibanuma, and Y. Isomura Chem. Pharm. Bull. 46 1998 1274
13. J. Posangi, M.A. Zar, and J.B. Harris Br. J. Pharmacol. 106 1992 307
14. P.G. Gilberg, S. Sundquist, and L. Nivelbrant Eur. J. Pharmacol. 349 1998 285
15. Separation of the diastereomers has been performed via chiral chromatography (Chiralpak AD column).
16. R. Baker, and J. Saunders Annu. Rep. Med. Chem. 24 1989 31
17. D.T. Newgreen, and A.M. Naylor Br. J. Pharmacol. 117 1996 107P
18. R.M. Wallis, and C.M. Napier Life Sci. 64 1999 395
19. J.M. Van Rossum, J.A.T.M. Hurkmans, and C.J.J. Wolters Arch. Int. Pharmacodyn. Ther. 143 1963 299
20. G. Lambrecht, R. Feifel, M. Wagner-Röder, C. Strohman, H. Zilch, R. Tacke, M. Waelbroeck, J. Christophe, H. Boddeke, and E. Mutschler Eur. J. Pharmacol. 168 1989 71
21. S. Swaminathan, and K.V. Narayanan Chem. Rev. 71 1971 429
22. D.J. Carlile, A.J. Stevens, E.I.L. Ashforth, D. Waghela, and J.B. Houston Drug Metab. Dispos. 26 1998 216
23. 3CN. See also: Ong, S.; Liu, H.; Pidgeon, C. J. Chromatogr. A, 1996, 728, 113.
24. R. Yuan, S. Madani, X. Wei, K. Reynolds, and S. Huang Drug Metab. Dispos. 30 2002 1311
25. M. Yaich, M. Popon, Y. Medard, and E.J. Aigrain Pharmacogenetics 8 1998 449
26. H. Postlind, A. Danielson, A. Lindgren, and S.H.G. Andersson Drug Metab. Dispos. 26 1998 289
27. K.C. Beaumont, N.J. Cussans, D.J. Nichols, and D.A. Smith Xenobiotica 28 1998 63
28. Novartis Pharmaceutical Corp. New Drug Application. 2004, NDA-021513.
29. Pharmacia and Upjohn. New Drug Application. 1998, NDA-020771.